Novus Therapeutics, Inc (NVUS) PT Lowered to $3.25 at Ascendiant Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts NVUS Hot Sheet
Price: $14.60 --0%
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Rating Summary:
3 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 48 | New: 9
Join SI Premium – FREE
Ascendiant Capital analyst Edward Woo lowered the price target on Novus Therapeutics, Inc (NASDAQ: NVUS) to $3.25 (from $3.50) while maintaining a Buy rating.
You May Also Be Interested In
- Boot Barn (BOOT) PT Lowered to $175 at Jefferies, 'We recommend buying BOOT'
- John B. Sanfilippo & Son, Inc. (JBSS) PT Lowered to $79 at Freedom Broker
- Veralto Corp. (VLTO) PT Raised to $135 at Jefferies, 'Accelerating Core Growth into 2027'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
